长链非编码 RNA-AWPPH 在冠状动脉疾病中的临床意义。

Clinical significance of lncRNA-AWPPH in coronary artery diseases.

机构信息

Department of Laboratory Medicine, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.

出版信息

Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11747-11751. doi: 10.26355/eurrev_202011_23826.

DOI:10.26355/eurrev_202011_23826

PMID:33275243

Abstract

OBJECTIVE

The aim of this study was to determine serum level of long non-coding RNA (lncRNA)-AWPPH in coronary artery disease (CAD) patients and its clinical significance as a serum marker.

PATIENTS AND METHODS

Serum levels of lncRNA-AWPPH in 132 CAD patients and 50 controls were detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Based on medical history of statin therapy, differential expressions of lncRNA-AWPPH in CAD patients were examined. Then, the correlation between lncRNA-AWPPH level and clinical data of CAD patients was analyzed. Moreover, risk factors influencing prognosis of CAD were assessed by multivariate logistic regression analysis.

RESULTS

It was found that lncRNA-AWPPH was highly expressed in serum of CAD patients, especially those receiving rosuvastatin therapy. LDL-C, hs-CRP, and serum lncRNA-AWPPH were independent risk factors for CAD, while HDL-C was favorable to CAD.

CONCLUSIONS

LncRNA-AWPPH is highly expressed in serum of CAD patients, which can be reduced by statin therapy, and it may be a potential serum marker for predicting the prognosis of CAD.

摘要

目的

本研究旨在确定冠状动脉疾病（CAD）患者血清中长链非编码 RNA（lncRNA）-AWPPH 的水平及其作为血清标志物的临床意义。

患者与方法

通过实时定量聚合酶链反应（qRT-PCR）检测 132 例 CAD 患者和 50 例对照者血清中的 lncRNA-AWPPH 水平。根据他汀类药物治疗的病史，检查 CAD 患者中 lncRNA-AWPPH 的差异表达。然后，分析 lncRNA-AWPPH 水平与 CAD 患者临床数据之间的相关性。此外，通过多变量逻辑回归分析评估影响 CAD 预后的危险因素。